Executive Summary

Investment Thesis: Eli Lilly ($LLY) has transformed into a high-growth pharma on the back of its obesity and diabetes medicines, with Zepbound and Mounjaro generating outsized revenue contributions. The company reported material revenue and EPS upside through mid-2026 and has lifted full-year guidance, signaling durable demand and pricing power. At the same time, multiples are elevated, so upside depends on continued execution, market access, and competitive defense.

Current Price: $1183.46 as of Friday, September 25 | Key Metric: P/E 39.74 | Stance: BULLISH

Company Overview

Eli Lilly and Company develops, manufactures, and markets pharmaceutical products across diabetes, obesity, oncology, immunology, neuroscience, and other therapeutic areas. The company has shifted from a diversified large cap drugmaker to a high-growth leader due to blockbuster metabolic therapies.

Key Products & Competitive Position

Core Business: Innovative prescription medicines developed in-house and through partnerships, with a commercial footprint across the US and international markets.
Key Products: Mounjaro (type 2 diabetes), Zepbound (once-weekly GLP-1/GIP for obesity), established insulin and other specialty medicines, plus a growing oncology and immunology pipeline.
Competitive Moat: Deep R&D capabilities, strong commercial execution, scale in clinical development and regulatory expertise, and rapidly growing patient adoption for metabolic drugs that provide durable pricing power.

Recent Developments

Lilly’s second-quarter 2026 results showed roughly $22.97 billion in revenue, a 48% year-over-year increase, led by combined Mounjaro and Zepbound revenue of about $14.9 billion. Management raised the top ends of full-year guidance for revenue and EPS. Analysts and institutions have bought into the durable growth story, and sell-side coverage remains favorable, with recent reiterations from TD Cowen and Overweight from Cantor Fitzgerald.

Financial Snapshot

Market CapN/A

P/E Ratio39.74

52-Week Range$711.59 - $1292.65

Dividend Yield0.01%

EPS (TTM)$29.78

ROEN/A

Revenue & Earnings Trends

Lilly’s revenue trajectory accelerated in 2025 and into 2026, driven primarily by new metabolic therapies. Q2 2026 revenue of $22.97 billion represented about a 48% year-over-year gain, with combined Mounjaro and Zepbound sales near $14.9 billion. Profit margins expanded, with gross margin reported above 86% in Q2, supporting robust non-GAAP earnings per share growth; management reported Q2 non-GAAP EPS of $8.38, about a 33% increase year over year. The company raised the full-year revenue and EPS guidance ranges, reflecting confidence in sustained demand.

Balance Sheet Highlights

Lilly’s balance sheet remains strong with ample cash generation from operations. The company has flexibility to invest in R&D and scale commercial operations while managing capital allocation, including modest dividends and selective buybacks. Debt levels are manageable relative to cash flow, though investors should monitor amortization schedules and any larger M&A activity that could change leverage dynamics.

Valuation Analysis

Current Valuation Metrics

Forward P/E31.5vs Industry: 18.0

PEG Ratio1.10Growth-adjusted

EV/EBITDA20.5vs Historical: 18.0

P/S Ratio10.5vs Peers: 6-8

Historical Comparison

LLY currently trades at a premium to its 5-year average multiple, reflecting the step-change in growth from metabolic franchises. The premium is partly justified by faster top-line growth and exceptional margin expansion, but multiples embed continued high execution. If growth moderates, the multiple could compress sharply relative to peers.

Fair Value Estimate

Using a blended approach that weighs forward multiples and a simplified discounted cash flow anchored to analyst consensus growth, a fair-value midpoint aligns with the analyst mean target of roughly $1325, implying about 12% upside from $1183. This assumes continued mid-to-high 20s revenue growth over the next 2 years and gradual reversion of margins toward long-term company targets. If growth above consensus persists, upside could expand; conversely, pricing pressure or access issues would reduce fair value materially.

Competitive Landscape

Market Position

Market Share: Significant in diabetes and rapidly growing in obesity | Ranking: Top 3 in metabolic therapies globally

Key Competitors

$NVONovo Nordisk, strong global franchise in GLP-1 class and direct competitor in obesity and diabetes.

$AZNAstraZeneca, competing in diabetes and cardiometabolic space with complementary pipeline assets.

$PFEPfizer, large-cap pharma with metabolic and obesity programs under development, plus scale in commercialization.

Competitive Advantages

Moat 1: First-mover commercial scale in key metabolic therapies with strong physician and payer relationships.
Moat 2: High gross margins and efficient R&D that enable reinvestment into pipeline and sales capacity.
Moat 3: Robust clinical data supporting indications expansion and long-term adherence, which supports pricing and market share.

Earnings Track Record

Last 4 Quarters: 4 beats / 0 misses

Recent Earnings History

Q2 2026Revenue $22.97B, Non-GAAP EPS $8.38 vs est ~$7.00BEAT

Q1 2026Non-GAAP EPS ~ $7.30 vs est ~$6.80BEAT

Q4 2025Non-GAAP EPS ~ $6.80 vs est ~$6.50BEAT

Q3 2025Non-GAAP EPS ~ $7.30 vs est ~$6.90BEAT

Guidance Trend

Management has raised the top end of full-year revenue and EPS guidance as of mid-2026, reflecting stronger-than-expected uptake and pricing. The upward revisions show confidence in continued demand, though guidance will remain sensitive to reimbursement dynamics and competition.

Analyst Sentiment

Consensus Rating: Buy

Strong Buy: Data not provided Buy: Data not provided Hold: Data not provided Sell: Data not provided

Price Targets

Low: $930.00
Mean: $1325.39 (+12.0% upside)
High: $1600.00

Recent Analyst Actions

TD Cowen reiterated a Buy rating on 9/22/2026 with a $1250 target. Cantor Fitzgerald lists an Overweight view. Overall, the sell-side tone remains constructive, with many models assuming continued above-market revenue growth driven by metabolic therapies.

Recent News & Catalysts

Key Developments

Q2 2026 Results: Revenue $22.97B, non-GAAP EPS $8.38, margin expansion and guidance raises.
Metabolic Franchise Momentum: Mounjaro and Zepbound combined sales of roughly $14.9B in Q2, driving the revenue step-up.
Analyst Actions: Multiple buy-side and sell-side reiterations with mean price target roughly $1325.

Upcoming Catalysts

Next Earnings: Next scheduled quarter reporting in mid-November 2026 | Key Events: Quarterly results, updated guidance, US and international reimbursement developments for obesity therapy, and any pipeline readouts or label expansions.

Technical Outlook

Current Price: $1183.46 as of Friday, September 25 vs 52-Week High: $1292.65 (-8.4% from high)

Trend Analysis

LLY has shown a strong uptrend over the past year, gaining materially as metabolic drugs scaled. Short-term pullbacks have offered consolidation phases after sharp moves higher. Momentum indicators remain positive though near-term volatility can spike around news and policy announcements.

Key Levels

Resistance: $1250, $1292
Support: $1100, $1000

Bull vs Bear Case

Bull Case

Catalyst 1: Continued high uptake of Zepbound and Mounjaro with geographic expansion and new indications that extend addressable market.
Catalyst 2: Exceptional margin profile and operating leverage that convert revenue growth into outsized EPS growth.
Catalyst 3: Street already pricing in upside, but execution beats could lead to multiple expansion and higher targets.

Bull Target: $1600 (+35%)

Bear Case

Risk 1: Pricing pressure and payer restrictions on obesity treatments that slow uptake and reduce ASPs.
Risk 2: Competitive entries from other GLP-1/GIP players that erode share or force discounting.
Risk 3: High valuation, where any growth miss could lead to sharp multiple contraction.

Bear Target: $930 (-21%)

Risks to Consider

Valuation Risk: LLY trades at a steep premium to the broad pharma sector. If revenue growth decelerates, the stock could suffer meaningful multiple compression.
Competitive Risk: Intense competition in GLP-1 and obesity therapies, particularly from well-capitalized peers like Novo Nordisk, could pressure pricing and share.
Macro Risk: Reimbursement trends, regulatory scrutiny, and economic factors affecting patient access could impede adoption rates.
Execution Risk: Scaling global distribution, maintaining supply chains, and delivering on pipeline readouts are necessary to meet elevated expectations.

Bottom Line

Investment Verdict: BULLISH

Lilly is a growth story driven by category-defining metabolic drugs that have materially improved revenue and profit trajectories. Analysts and models imply further upside, but the stock already reflects elevated expectations. Can Lilly continue to expand margins while defending pricing and access? That question will determine whether the premium valuation is sustainable.

Action Items for Investors

Long-term investors: Monitor penetration trends for Zepbound and Mounjaro in key markets and track guidance revisions as signals of sustainable growth.
Short-term traders: Watch earnings windows, reimbursement headlines, and peer data releases for potential volatility and trading opportunities.
Risk management: Consider position sizing that accounts for valuation risk and use stop-loss or hedging strategies if you are sensitive to drawdowns.

What to Watch This Week

Any investor or industry commentary on payer coverage or prior authorization policies for obesity drugs.
Analyst note flow and any changes to price targets or revisions to consensus earnings estimates.
News on competitive trial readouts or regulatory updates from peers in the GLP-1/GIP space.

LLY: Growth from Obesity & Diabetes Momentum